Pharmafile Logo

Lucid Group has four programmes shortlisted for PMEA 2019

Lucid is celebrating four of their programmes being shortlisted in four categories at this year’s PMEAs

- PMLiVE

Lucid’s talent for partnering with its clients to create magical healthcare communications is evident as they celebrate four of their programmes making the PMEA 2019 finals.

Jan Steele, Lucid Group COO and Co-founder commented, “2019 has been a transformative year for Lucid Group. We have gone through two acquisitions, allowing us to increase capability and reach. With all this change, it is a testament to our team’s dedication and passion that they continue to deliver outstanding work for our clients. I do not doubt that as we move into 2020 we will continue this incredible momentum with our work helping to transform more lives than ever before.”

PMEA recognises the achievements of responsible customer-centric business practices that provide patients with meaningful outcomes. The winners will be announced on Wednesday 27 November 2019 at the Royal Lancaster London.

More details about the shortlisted programmes can be found below:

Category: Excellence in Healthcare Professional Education and Support Programmes:   
CLEAR HORIZONS: A new era of psoriasis care
INSPIRE: Improving outcomes in paediatric cardiology

Category: Excellence in Capability Development
Global Medical Affairs as CATALYSTs for change

Category: Excellence in Innovation
DermDialogue: Bringing innovation to MSL‐led education

Excellence in Rare Diseases and Orphan Drugs
INSPIRE: Improving outcomes in paediatric cardiology

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD